Last reviewed · How we verify
Placebo matching Dacarbazine
This is a placebo control arm matching the active comparator dacarbazine, containing no active pharmaceutical ingredient.
This is a placebo control arm matching the active comparator dacarbazine, containing no active pharmaceutical ingredient. Used for Control arm in Phase 3 trial (specific indication unknown without trial protocol).
At a glance
| Generic name | Placebo matching Dacarbazine |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
In a Phase 3 clinical trial, this placebo is formulated to match dacarbazine (an alkylating agent used in melanoma and other cancers) in appearance, administration route, and schedule, but contains no active drug. It serves as the control arm to assess the efficacy and safety of the actual dacarbazine treatment or another investigational agent being tested against it.
Approved indications
- Control arm in Phase 3 trial (specific indication unknown without trial protocol)
Common side effects
Key clinical trials
- ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids (PHASE2)
- Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) (PHASE2)
- A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) (PHASE2, PHASE3)
- Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (PHASE3)
- Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM) (PHASE2)
- A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matching Dacarbazine CI brief — competitive landscape report
- Placebo matching Dacarbazine updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI